ImmunityBio Reports Positive Long-Term Phase 3 Data for ANKTIVA in Bladder Cancer

Key Facts

Phase 3 QUILT-3.032 data showed 84% of patients avoided radical cystectomy for three years when treated with ANKTIVA plus BCG. Business Wire reported that ImmunityBio published these long-term clinical results in the Journal of Urology, highlighting sustained complete responses and high rates of bladder preservation in patients with BCG-unresponsive bladder cancer.

IBRX closed at $10 on October 15, 2026, with the stock reaching a session high of $10.5 and a low of $9.82. The publication provides clinical validation of ANKTIVA's long-term efficacy, specifically noting its ability to prevent surgical bladder removal for over 53 months in certain clinical cases.